A Novel Anti-CD44 Variant 3 Monoclonal Antibody C44Mab-6 Was Established for Multiple Applications
Hiroyuki Suzuki(Tohoku University), Yukinari Kato(Tohoku University)
Cited by 14
Related Papers
Molecular Identification of Aggrus/T1α as a Platelet Aggregation-inducing Factor Expressed in Colorectal Tumors
|Journal of Biological Chemistry|2003|266
A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma
|Oncology Reports|2020|46
Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma
|Oncotarget|2018|45
A Progressive Early Mobilization Program Is Significantly Associated With Clinical and Economic Improvement: A Single-Center Quality Comparison Study
|Critical Care Medicine|2019|43
The safety of a novel early mobilization protocol conducted by ICU physicians: a prospective observational study
|Journal of Intensive Care|2018|41